MDMark Deneau

Mark Deneau

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mark Deneau has a total of 240 co-authors. Here are the top co-authors by number of shared publications:

  • Mercedes Martinez

    Department of Pediatrics, Vagelos College of Physicians and Surgeons, Columbia University, New York City, New York, USA

    7 shared publications
  • Amanda Ricciuto

    Division of Gastroenterology, Hepatology & Nutrition, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada

    6 shared publications
  • Binita M. Kamath

    Division of Gastroenterology, Hepatology and Nutrition, The Children's Hospital of Philadelphia and the University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA

    6 shared publications
  • Tamir Miloh

    Department of Pediatrics,University of Miami,Miami,FL

    6 shared publications
  • Cara Mack

    University of Colorado School of Medicine,Aurora,CO

    5 shared publications
  • Katryn N. Furuya

    Department of Pediatrics,Mayo Clinic,Rochester,MN

    5 shared publications

Latest Publications

  • Open Access

    The Childhood Liver Disease Research Network's prospective characterization of pediatric primary sclerosing cholangitis

    by Cara L. Mack, Alexander G. Miethke, Kieran Hawthorne, Lisa Henn, Simon Horslen, Estella M. Alonso, Nitika A. Gupta, Shikha S. Sundaram, Rohit Kohli, Molly Bozic, et al.

    Background: Primary sclerosing cholangitis (PSC) is a rare biliary fibrosing disease that leads to significant morbidity and the need for liver transplantation. The Childhood Liver Disease Research Network is conducting a prospective, observational longitudinal study to define the natural history of pediatric PSC. The aim of this report is to characterize the clinical phenotypes of the first 175 children enrolled in the PSC study and to determine correlations of specific phenotypes with clinical and laboratory characteristics. Methods: Data collected included a history of inflammatory bowel disease (IBD), autoimmune hepatitis (AIH), laboratories, autoantibodies, liver stiffness measurements (LSM), medications, and IBD activity. Comparison of phenotypes with/without IBD and/or AIH, and small-duct versus large-duct PSC was performed. Results: The median age at enrollment was 16.1 years, 60% were male, 78% had large-duct PSC, and the median duration of PSC was 2.2 years. The predominant phenotype was PSC/IBD, and 96% had quiescent/mild IBD. The entire cohort had evidence of mild liver disease based on biochemistries and LSMs; <10% had evidence of portal hypertension. Higher LSMs were associated with elevated liver biochemistries. There were no significant characteristics that differentiated the phenotypes; however, there was more frequent autoantibody positivity in PSC/IBD and higher LSMs in PSC/AIH overlap syndrome. Conclusions: This prospective cohort of pediatric PSC revealed mild liver disease in the majority. Laboratory biomarkers of liver injury and fibrosis were associated with LSM severity, suggesting LSM as a reliable tool to monitor PSC progression. This dataset encompasses a well-phenotyped cohort of children with PSC that will be followed prospectively for longitudinal assessment of progression of disease, as well as a model for stratification within future treatment trials.

  • Open Access

    Artificial intelligence predicts recurrent autoimmune hepatitis after liver transplantation in a multicenter cohort study

    by Mamatha Bhat, Yingji Sun, Praveen Manickavel, Saba Maleki, Vincenzo Ronca, Bettina E Hansen, Gideon Hirschfield, Saleh Elwir, Mohamad Alsaed, Piotr Milkiewicz, et al.

    Background: Autoimmune hepatitis (AIH) is an important indication for liver transplantation (LT), but recurrence affects over 30% of recipients, threatening long-term survival. Current strategies to prevent recurrence and progressive graft fibrosis remain suboptimal, with limited evidence to guide selection of immunosuppressive regimens. We aimed to develop a dynamic, individualized, artificial intelligence–powered model for post-transplant recurrent AIH. Methods: We conducted a multicenter, retrospective cohort study of 706 patients who underwent LT for AIH between January 1987 and June 2020 at 33 centers in North America, South America, Europe, and Asia. We trained 4 predictive machine learning models—Logistic Regression, Random Forest, XGBoost, and Gradient Boost—to predict recurrent AIH (rAIH) using 62 clinical and laboratory variables, including demographic, biochemical features, and immunosuppressive drugs up to 1-year post-transplant. Feature importance was assessed using SHapley Additive exPlanations (SHAP) to enable interpretability at both individual and population levels. Results: AIH recurred in 16.5% of patients after LT. SHAP analysis identified younger age at LT, higher necroinflammatory activity in the explanted liver, and elevated MELD score at LT as key predictors of rAIH in the overall population. Tacrolimus-based therapy was associated with a lower risk of recurrence, while cyclosporine use conferred a higher risk. The addition of long-term prednisone to a regimen of tacrolimus and mycophenolate mofetil did not provide additional protective effect against rAIH. Conclusions: Our AI-powered clinical decision model provides personalized prediction of post-transplant rAIH. While it offers insight into modifiable and non-modifiable predictors, prospective validation is required before informing immunosuppressive decisions.

  • Open Access

    Longitudinal GGT Trajectories Identify Prognostic Phenotypes in Paediatric Primary Sclerosing Cholangitis

    by Daniela Denier, Yiming (Emmett Peng, Mansi Amin, Madeleine Aumar, Marcus Auth, Eleonora Druve Tavares Fagundes, Wael El-Matary, Alexandre R. Ferreira, Katryn N. Furuya, Nitika Gupta, et al.

  • Open Access

    Bayesian Sensitivity Analysis for Causal Estimation With Time‐Varying Unmeasured Confounding

    by Yushu Zou, Liangyuan Hu, Amanda Ricciuto, Mark Deneau, Kuan Liu

    Causal inference relies on the untestable assumption of no unmeasured confounding to ensure the causal parameter of interest is identifiable. Sensitivity analysis quantifies the unmeasured confounding's impact on causal estimates. Among sensitivity analysis methods proposed in the literature, the latent confounder approach is favored for its intuitive interpretation via the use of bias parameters to specify the relationship between the observed and unobserved variables, and the sensitivity function approach directly characterizes the net causal effect of the unmeasured confounding without explicitly introducing latent variables to the causal models. In this paper, we developed and extended these two sensitivity analysis approaches, namely the Bayesian sensitivity analysis with latent confounding variables and the Bayesian sensitivity function approach for the estimation of time‐varying treatment effects with longitudinal observational data subjected to time‐varying unmeasured confounding. We investigated the performance of these methods in a series of simulation studies and applied them to a multicenter pediatric disease registry to provide practical guidance on their implementation.


  • Reply: Insurance should cover vancomycin for primary sclerosing cholangitis

    by Christopher L. Bowlus, Lionel Arrivé, Annika Bergquist, Mark Deneau, Lisa Forman, Sumera I. Ilyas, Keri E. Lunsford, Mercedes Martinez, Gonzalo Sapisochin, Rachna Shroff, et al.


  • Reply: Living donor liver transplantation for people with PSC

    by Lisa M. Forman, Gonzalo Sapisochin, David N. Assis, Lionel Arrivé, Annika Bergquist, Christopher L. Bowlus, Mark Deneau, Sumera I. Ilyas, Keri E. Lunsford, Mercedes Martinez, et al.


  • Top Cited Papers

    AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma

    by Christopher L. Bowlus, Lionel Arrivé, Annika Bergquist, Mark Deneau, Lisa Forman, Sumera I. Ilyas, Keri E. Lunsford, Mercedes Martinez, Gonzalo Sapisochin, Rachna Shroff, et al.


  • Recurrence of Primary Sclerosing Cholangitis After Liver Transplant in Children: An International Observational Study

    by Mercedes Martinez, Emily R. Perito, Pamela Valentino, Cara L Mack, Madeleine Aumar, Annemarie Broderick, Laura G. Draijer, Eleonora D.T. Fagundes, Katryn N. Furuya, Nitika Gupta, et al.

    Background and Aims: Recurrent primary sclerosing cholangitis (rPSC) following liver transplant (LT) has a negative impact on graft and patient survival; little is known about risk factors for rPSC or disease course in children. Approach and Results: We retrospectively evaluated risk factors for rPSC in 140 children from the Pediatric PSC Consortium, a multicenter international registry. Recipients underwent LT for PSC and had >90 days of follow‐up. The primary outcome, rPSC, was defined using Graziadei criteria. Median follow‐up after LT was 3 years (interquartile range 1.1‐6.1). rPSC occurred in 36 children, representing 10% and 27% of the subjects at 2 years and 5 years following LT, respectively. Subjects with rPSC were younger at LT (12.9 vs. 16.2 years), had faster progression from PSC diagnosis to LT (2.5 vs. 4.1 years), and had higher alanine aminotransferase (112 vs. 66 IU/L) at LT (all P < 0.01). Inflammatory bowel disease was more prevalent in the rPSC group (86% vs. 66%; P = 0.025). After LT, rPSC subjects had more episodes of biopsy‐proved acute rejection (mean 3 vs. 1; P < 0.001), and higher prevalence of steroid‐refractory rejection (41% vs. 20%; P = 0.04). In those with rPSC, 43% developed complications of portal hypertension, were relisted for LT, or died within 2 years of the diagnosis. Mortality was higher in the rPSC group (11.1% vs. 2.9%; P = 0.05). Conclusions: The incidence of rPSC in this cohort was higher than previously reported, and was associated with increased morbidity and mortality. Patients with rPSC appeared to have a more aggressive, immune‐reactive phenotype. These findings underscore the need to understand the immune mechanisms of rPSC, to lay the foundation for developing new therapies and improve outcomes in this challenging population.


  • Oral Vancomycin, Ursodeoxycholic Acid, or No Therapy for Pediatric Primary Sclerosing Cholangitis: A Matched Analysis

    by Mark R. Deneau, Cara Mack, Douglas Mogul, Emily R. Perito, Pamela L. Valentino, Achiya Z. Amir, Matthew DiGuglielmo, Laura G. Draijer, Wael El‐Matary, Katryn N. Furuya, et al.

    Background and Aims: Many children with primary sclerosing cholangitis (PSC) receive oral vancomycin therapy (OVT) or ursodeoxycholic acid (UDCA). There is a paucity of data on whether these medications improve outcomes. Approach and Results: We analyzed retrospective data from the Pediatric PSC Consortium. Children treated with OVT were matched 1:1:1 to those treated with UDCA or managed with observation (no treatment) based on the closest propensity score, ensuring similar baseline characteristics. Two hundred sixty‐four patients (88 each with OVT, UDCA, or observation) had matching propensity scores and were similar in demographics, phenotype, immunosuppression, baseline biochemistry, and hepatic fibrosis. After 1 year in an intention‐to‐treat analysis, all outcome metrics were similar regardless of treatment group. In OVT, UDCA, and untreated groups, respectively: Gamma‐glutamyltransferase normalized in 53%, 49%, and 52% (P = not significant [NS]), liver fibrosis stage was improved in 20%, 13%, and 18% and worsened in 11%, 29%, and 18% (P = NS), and the 5‐year probability of liver transplant listing was 21%, 10%, and 12% (P = NS). Favorable outcome was associated with having a mild phenotype of PSC and minimal hepatic fibrosis. Conclusions: We presented the largest‐ever description of outcomes on OVT in PSC and compared them to carefully matched patients on UDCA or no therapy. Neither OVT nor UDCA showed improvement in outcomes compared to a strategy of observation. Patients progressed to end‐stage liver disease at similar rates. Spontaneous normalization of biochemistry is common in children receiving no therapy, particularly in the majority of children with a mild phenotype and an early stage of disease. Placebo‐controlled treatment trials are needed to identify effective treatments for pediatric PSC.